These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
379 related articles for article (PubMed ID: 16022920)
41. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. Kelly K; Lovato L; Bunn PA; Livingston RB; Zangmeister J; Taylor SA; Roychowdhury D; Crowley JJ; Gandara DR; Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808 [TBL] [Abstract][Full Text] [Related]
42. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741 [TBL] [Abstract][Full Text] [Related]
43. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897 [TBL] [Abstract][Full Text] [Related]
44. A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Sculier JP; Paesmans M; Lecomte J; Van Cutsem O; Lafitte JJ; Berghmans T; Koumakis G; Florin MC; Thiriaux J; Michel J; Giner V; Berchier MC; Mommen P; Ninane V; Klastersky J; Br J Cancer; 2001 Nov; 85(10):1444-51. PubMed ID: 11720426 [TBL] [Abstract][Full Text] [Related]
45. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V; Lung Cancer; 2002 Oct; 38(1):59-63. PubMed ID: 12367794 [TBL] [Abstract][Full Text] [Related]
46. Topotecan in the first-line treatment of small cell lung cancer. Stewart DJ Oncologist; 2004; 9 Suppl 6():33-42. PubMed ID: 15616148 [TBL] [Abstract][Full Text] [Related]
47. Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Perez EA; Geoffroy FJ; Hillman S; Johnson EA; Farr GH; Tazelarr HD; Hatfield AK; Krook JE; Maillard JA; Levitt R; Marks RS Lung Cancer; 2004 Jun; 44(3):347-53. PubMed ID: 15140548 [TBL] [Abstract][Full Text] [Related]
48. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience. Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097 [TBL] [Abstract][Full Text] [Related]
49. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613 [TBL] [Abstract][Full Text] [Related]
50. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer. Lee DH; Kim SW; Suh C; Lee JS; Ahn JS; Ahn MJ; Park K; Na II; Lee JC; Ryoo BY; Yang SH Cancer; 2010 Jan; 116(1):132-6. PubMed ID: 19904804 [TBL] [Abstract][Full Text] [Related]
51. [Teniposide and cisplatin compared with etoposide and cisplatin for treatment of small cell lung cancer]. Fan Y; Huang ZY; Zhang YP; Sun L Ai Zheng; 2002 Dec; 21(12):1368-71. PubMed ID: 12520751 [TBL] [Abstract][Full Text] [Related]
52. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Stathopoulos GP; Rigatos SK; Christodoulou C; Malamos NA; Deliyiannis F; Stathopoulos JG; Skarlos DV Cancer Chemother Pharmacol; 2004 Sep; 54(3):259-64. PubMed ID: 15127231 [TBL] [Abstract][Full Text] [Related]
53. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562 [TBL] [Abstract][Full Text] [Related]
54. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Shah C; Ready N; Perry M; Kirshner J; Gajra A; Neuman N; Garziano S Lung Cancer; 2007 Jul; 57(1):84-8. PubMed ID: 17399850 [TBL] [Abstract][Full Text] [Related]
55. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients]. Cok G; Göksel T; Soyer S; Atil H; Güzelant A; Aysan T Tuberk Toraks; 2006; 54(2):161-7. PubMed ID: 16924573 [TBL] [Abstract][Full Text] [Related]
56. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up. Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811 [TBL] [Abstract][Full Text] [Related]
57. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer. Lee DH; Kim SW; Bae KS; Hong JS; Suh C; Kang YK; Lee JS Clin Cancer Res; 2007 Oct; 13(20):6182-6. PubMed ID: 17947485 [TBL] [Abstract][Full Text] [Related]
58. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Hong J; Jung M; Kim YJ; Sym SJ; Kyung SY; Park J; Lee SP; Park JW; Cho EK; Jeong SH; Shin DB; Lee JH Cancer Chemother Pharmacol; 2012 Jan; 69(1):215-20. PubMed ID: 21691745 [TBL] [Abstract][Full Text] [Related]
59. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. Socinski MA; Weissman C; Hart LL; Beck JT; Choksi JK; Hanson JP; Prager D; Monberg MJ; Ye Z; Obasaju CK J Clin Oncol; 2006 Oct; 24(30):4840-7. PubMed ID: 17050869 [TBL] [Abstract][Full Text] [Related]
60. [Comparison of 2 cisplatin and etoposide dosages in relapsing small cell lung cancer]. Trillet-Lenoir V; Lasset C; Arpin D; Bohas C; Riou R; Perol M; Fournel P; Rebattu P; Caillet B; Pacheco Y Bull Cancer; 1992; 79(12):1173-81. PubMed ID: 1339011 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]